Ocugen doses first patient in Phase 3 gene therapy trial for dry AMD
Tweet Send to a Friend
Ocugen, Inc. (NASDAQ: OCGN) announced that the first patient has been dosed in its global Phase 3 registrational trial, ArMaDa3 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
